| Company/Division name | Novo Nordisk |
| Parent company | Novo Nordisk Foundation |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2021 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 1300 |
| Country(ies) from which reshored: | Denmark |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals, pharmaceutical |
| Product(s) reshored | oral semaglutide drugs, oral biologic, Rybelsus |
| What domestic positive factors made reshoring more attractive? | Infrastructure, Lead time/Time to market, Under-utilized capacity |
